China Bio-Immunity Corporation Completes Share Exchange and Reverse Merger

DALIAN, China , Aug. 6 /Xinhua-PRNewswire-FirstCall/ -- China Bio-Immunity Corporation (OTC Bullets and Board: CHHB) (''China Bio-Immunity" or "the Company''), today announced that it has entered into a share exchange agreement with Lawford Asia...


About China Bio-Immunity

Based in Dalian, China , China Bio-Immunity develops, produces, manufactures and markets internally developed vaccine-based prophylactics and therapeutics. The Company has sales and marketing efforts in the 24 main provinces and major cities in the People's Republic of China (''P.R.C.'') and its principal products, its Rabies Vaccine and Mumps Vaccine, are sold and distributed by a network of approximately 100 wholesale distributors, as well as through more than 2,200 retail customers. In addition to the current distribution structure, the Company plans to further market its products through distribution agreements with local agents in several developing countries, including, but not limited to India , South Africa , and countries throughout Southeast Asia . To learn more about the Company, visit http://www.jgad-bio.com .

Safe Harbor Statement

This press release includes certain statements that are not descriptions of historical facts, but are forward-looking statements. Such statements include, among others, those concerning our expected financial performance and strategic and operational plans, our future operating results, our expectations regarding the market for security and surveillance products, our expectations regarding the continued growth of the security and surveillance market, as well as all assumptions, expectations, predictions, intentions or beliefs about future events. You are cautioned that any such forward-looking statements are not guarantees of future performance and that a number of risks and uncertainties could cause our actual results to differ materially from those anticipated, expressed or implied in the forward-looking statements. These risks and uncertainties include, but not limited to, the factors mentioned in the ''Risk Factors'' section of the Form 8-K of the Share Exchange Agreement that has been filed with the Securities Exchange Commission, or SEC. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis retrieval system (EDGAR) at http://www.sec.gov . The words ''believe'', ''expect'', ''anticipate'', ''project'', ''targets'', ''optimistic'', ''intend'', ''aim'', ''will'' or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward- looking statements. The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law.

SOURCE China Bio-Immunity Corporation